Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Bibliography

• Kroemer G, Galuzzi I, Kepp O, Zitvogel I. Immunogenic cell death in cancer therapy. Ann Rev Immunol 2013;31:51-72
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014;4:6-16
   PubMedGoogle Scholar
• Schirrmacher V, Fournier P. Editorial: Harnessing oncolytic virus-mediated anti-tumor immunity. Front Oncol 2014.4:337-8. Available from: http://journal.frontiersin.org/researchtopic/1613
   Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17
   PubMedGoogle Scholar
• Russel SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70
   PubMed Web of Science ®Google Scholar
• Csatary LK, Gosztonyi G, Szeberenyi J, et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004;67:83-93
   PubMed Web of Science ®Google Scholar
• Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast and ovarian cancer. J Clin Oncol 1997;15:1354-66
   PubMed Web of Science ®Google Scholar
• Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13:221-8
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR. Newcastle disease virus as an antineoplastic agent. Cancer 1965;7:863-8
   Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2013;2:936-75
   PubMedGoogle Scholar
• Lam HY, Yeap SK, Rasoli M, et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. J Biomed Biotechnol 2011;2011:718710
   PubMed Web of Science ®Google Scholar
• De Leeuw O, Peeters B. Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol 1999;80:131-6
   PubMed Web of Science ®Google Scholar
• Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 2012;40:287-98
   PubMed Web of Science ®Google Scholar
• Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol 2009;34:971-82
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S, et al. 5`-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7
   PubMed Web of Science ®Google Scholar
• Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol 2005;79:12944-51
   PubMed Web of Science ®Google Scholar
• Park MS, Garcia-Sastre A, Cros JF, et al. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003;77:9522-32
   PubMed Web of Science ®Google Scholar
• Alexander DJ. Newcastle Disease. Kluwer Academic; 1988
   Google Scholar
• Miller LT, Yates VJ. Reactions of human sera to avian adenoviruses and Newcastle disease virus. Avian Dis 1971;15(4):303-7
   Google Scholar
• Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012;7(3):347-67
   PubMed Web of Science ®Google Scholar
• Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66
   PubMed Web of Science ®Google Scholar
• Nagai Y, Hamaguchi M, Toyoda T. Molecular biology of Newcastle disease virus. Prog Vet Microbiol Immunol 1989;5:16-64
   PubMedGoogle Scholar
• Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006;80:7522-34
   PubMed Web of Science ®Google Scholar
• Kumar R, Tiwari AK, Chaturvedi U, et al. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol 2012;167:2005-22
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35:495-516
   PubMed Web of Science ®Google Scholar
• Chng WC, Stanbridge EJ, Yusoff K, Shafee N. The oncolytic activity of Newcastle disease virus in clear cell carcinoma cells in normoxic and hypoxic conditions: The interplay between VHL and interferon-beta signaling. J Interferon Cytokine Res 2013;33:346-54
   PubMed Web of Science ®Google Scholar
• Elankumaran S, Chavan V, Quiao D, et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 2010;84(8):3835-44
   PubMed Web of Science ®Google Scholar
• Fiola C, Peeters B, Fournier P, et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defense. Int J Cancer 2006;119(2):328-38
   PubMed Web of Science ®Google Scholar
• Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int J Oncol 2009;34(4):971-82
   PubMed Web of Science ®Google Scholar
• Wilden H, Schirrmacher V, Fournier P. Important role of interferon-regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. Int J Oncol 2011;39(2):493-504
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006;80(11):5145-55
   PubMed Web of Science ®Google Scholar
• Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 2012;40(1):287-98
   PubMed Web of Science ®Google Scholar
• Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 2011;85(12):6015-23
   PubMed Web of Science ®Google Scholar
• Lazar I, Yacoov B, Shiloach T, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis Livin. J Virol 2010;84(1):639-46
   PubMed Web of Science ®Google Scholar
• Puhlmann J, Puehler F, Mumberg D, et al. Rac 1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 2010;29(15):2205-16
   PubMed Web of Science ®Google Scholar
• Abdullah JM, Mustafa Z, Ideris A. Newcastle Disease Virus interaction in targeted therapy against proliferation and invasion pathways of Glioblastoma multiforme. Biomed Res Int 2014;2014:386470
   PubMedGoogle Scholar
• Koks CAE, De Vleeschouwer S, Graf N, Van Gool SW. Immune suppression during oncolytic virotherapy for high-grade glioma; yes or no? J of Cancer 2015;6:203-17
   PubMed Web of Science ®Google Scholar
• Fábián Z, Csatary CM, Szeberényi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007;81:2817-30
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Diff 2008;15:3-12
   PubMed Web of Science ®Google Scholar
• Meng C, Zhou Z, Yu S, et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol 2012;157:1011-18
   PubMed Web of Science ®Google Scholar
• Meng G, Xia M, Wang D, et al. Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget 2014;5:6365-74
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008;68:6889-95
   PubMed Web of Science ®Google Scholar
• Fournier P, Arnold A, Wilden H, Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol 2012;40:840-50
   PubMed Web of Science ®Google Scholar
• Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009;83:8108-21
   PubMed Web of Science ®Google Scholar
• Zeng J, Fournier P, Schirrmacher V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002;297:19-30
   PubMed Web of Science ®Google Scholar
• Molouki A, Hsu YT, Jahanshiri F, et al. The matrix (M) protein of Newcastle disease virus binds to human Bax trough its BH3 domain. Virol J 2011;8(1):385
   PubMed Web of Science ®Google Scholar
• Washburn B, Weigand MA, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 2003;170:1814-21
   PubMed Web of Science ®Google Scholar
• Umansky V, Beckhove P, Rocha M, et al. Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol 1996;8:491-8
   PubMed Web of Science ®Google Scholar
• Jurianz K, Haas C, Hubbe M, et al. Adhesive function of Newcastle-disease virus hemagglutinin in tumor-host interaction. Int J Oncol 1995;7:539-45
   PubMed Web of Science ®Google Scholar
• Termeer CC, Schirrmacher V, Bröcker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000;7:316-23
   PubMed Web of Science ®Google Scholar
• Ertel C, Millar NS, Emmerson PT, et al. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 1993;23:2592-6
   PubMed Web of Science ®Google Scholar
• Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002;21:85-93
   PubMed Web of Science ®Google Scholar
• Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994;54:6017-21
   PubMed Web of Science ®Google Scholar
• Wei D, Sun N, Nan G, et al. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther 2012;23(7):700-10
   PubMed Web of Science ®Google Scholar
• Koks CA, Garg AD, Ehrhardt M, et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015;136:E313-25
   PubMed Web of Science ®Google Scholar
• Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 2007;31:1009-19
   PubMed Web of Science ®Google Scholar
• Altomonte J, Marozin S, Schmidt RM, Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18(2):275-84
   PubMed Web of Science ®Google Scholar
• Song KY, Wong J, Gonzalez L, et al. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med 2010;88(6):589-96
   PubMed Web of Science ®Google Scholar
• Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010;9(10):2761-9
   PubMed Web of Science ®Google Scholar
• Merigan TCDCE. Finkelstein MS, Clever L, et al. Clinical studies employing interferon inducers in man and animals. Ann N Y Acad Sci 1970;173:746-59
   Web of Science ®Google Scholar
• Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detec Prev 1993;17:619-27
   PubMedGoogle Scholar
• Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13(1):221-8
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Lorence RM, Hirte HW, et al. An optimized clinical regime for the oncolytic virus PV701. Clin Cancer Res 2007;13(3):977-85
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR, Torbin AH. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunological responses. Cancer 1977;40(2):672-9
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated post-surgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992;9(4):169-71
   PubMedGoogle Scholar
• Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8+ T cell repertoire. Mol Med 1998;4(12):783-94
   PubMed Web of Science ®Google Scholar
• Plager C, Bowen JM, Fenoglio C, et al. Adjuvant immunotherapy with Newcastle disease virus oncolysate of M.D. Anderson (MDAH) stage III-B malignant melanoma. Proc Am Soc Clin Oncol 1986;5:137a
   Google Scholar
• Voit C, Kron M, Schwurzer-Voit M, Sterry W. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease. J Dtsch Dermatol Ges 2003;1(2):120-5
   PubMedGoogle Scholar
• Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 1995;13(3):171-3
   PubMed Web of Science ®Google Scholar
• Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor-cell vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994;91(16):7430-4
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Schild HJ, Gückel B, von Hoegen P. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens. Immunol Cell Biol 1993;71:311-26
   PubMed Web of Science ®Google Scholar
• Schild H, von Hoegen P, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Cancer Immunol Immunother 1989;28:22-8
   PubMed Web of Science ®Google Scholar
• von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol 1990;126(1):80-90
   PubMed Web of Science ®Google Scholar
• Heicappell R, Schirrmacher V, von Hoegen P, et al. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 1986;37:569-77
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Haas C, Bonifer R, et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999;6:63-73
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Ahlert T, Pröbstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol 1998;25:677-96
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004;22:745-63
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines 2014;13:117-30
   PubMed Web of Science ®Google Scholar
• Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996;2(1):21-8
   PubMed Web of Science ®Google Scholar
• Schlag P, Manasterski M, Gerneth T, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992;35(5):325-30
   PubMed Web of Science ®Google Scholar
• Schulze A, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009;58(1):61-9
   PubMed Web of Science ®Google Scholar
• Möbus V, Horn S, Stöck M, Schirrmacher V. Tumor cell vaccination for gynecological tumors. Hybridoma 1993;12(5):543-7
   PubMed Web of Science ®Google Scholar
• Pomer S, Thiele R, Staehler G, et al. Tumor vaccination with and without adjuvant interleukin 2 in renal cell carcinoma. A clinical contribution to the development of effective specific immunization. Urologe 1995;34(3):215-20
   PubMed Web of Science ®Google Scholar
• Karcher J, Dyckhoff G, Beckhove P, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004;64:8057-61
   PubMed Web of Science ®Google Scholar
• Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004;22:4272-81
   PubMed Web of Science ®Google Scholar
• Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterology 2003;9(3):495-8
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Exp Rev Vaccines 2009;8(1):1-16
   PubMed Web of Science ®Google Scholar
• Hoover HCJr, Brandhorst JS, Peters LC, et al. Adjuvant active-specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11(3):390-9
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and III colon cancer: a randomized trial. Lancet 1999;353(9150):345-50
   PubMed Web of Science ®Google Scholar
• Nava S, Lisini D, Pogliani S, et al. Safe and reproducible preparation of functional dendritic cells for immunotherapy in glioblastoma patients. Stem Cells Transl Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Zaslavsky E, Hershberg U, Seto J, et al. Antiviral response dictated by choreographed cascade of transcription factors. J Immunol 2010;184:2908-17
   PubMed Web of Science ®Google Scholar
• Fournier P, Arnold A, Schirrmacher V. Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON 2009;14(Suppl 1):S111-22
   Google Scholar
• Bai L, Koopmann J, Fiola C, et al. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002;21:685-94
   PubMed Web of Science ®Google Scholar
• Wenner CA, Guler ML, Macatonia SE, et al. Roles of IFN-a and IFN-ß in IL-12-induced T helper-1 development. J Immunol 1996;156:1442-7
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Stücker W, Lulei M, et al. Long-term survival of a breast cancer patient upon immune and virotherapy: a case report. Immunother 2015; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015;519:366-9
   PubMed Web of Science ®Google Scholar
• Donnelly O, Ilett E, Kottke T, et al. Cytokine-enhanced intravenous oncolytic virotherapy. Lancet 2014;383:S42
   Google Scholar
• Altomonte J, Marozin S, Schmidt RM, Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18:275-84
   PubMed Web of Science ®Google Scholar
• Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009;17:697-706
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang X, Wang X, et al. Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology 2012;55:276-86
   PubMed Web of Science ®Google Scholar
• Janke M, Peeters B, Zhao H, et al. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 2008;33:823-32
   PubMed Web of Science ®Google Scholar
• Janke M, Peeters B, deLeeuw O, et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 2007;14:1639-49
   PubMed Web of Science ®Google Scholar
• Niu Z, Bai F, Sun T, et al. Recombinant Newcastle disease virus expressing IL-15 demonstrates promising antitumor efficiency in melanoma model. Technol Cancer Res Treat 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Susta L, Cornax I, Diel DG, et al. Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens. Microb Pathog 2013;6:73-83
   Web of Science ®Google Scholar
• Pühler F, Willuda J, Puhlmann J, et al. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther 2008;15:371-83
   PubMed Web of Science ®Google Scholar
• Shobana R, Samal SK, Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J Virol 2013;87:3792-800
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Schirrmacher V. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Int J Oncol 2009;34:951-62
   PubMed Web of Science ®Google Scholar
• Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15(23):7246-55
   PubMed Web of Science ®Google Scholar
• Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014;123:1327-35
   PubMed Web of Science ®Google Scholar
• Aigner M, Janke M, Lulei M, et al. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 2008;32:777-89
   PubMed Web of Science ®Google Scholar
• Fournier P, Aigner M, Schirrmacher V. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Int J Oncol 2010;37:1203-17
   PubMed Web of Science ®Google Scholar
• Fournier P, Aigner M, Schirrmacher V. Transcriptome analysis and cytokine profiling of naïve T cells stimulated by a tumor vaccine via CD3 and CD25. Int J Oncol 2010;37:1439-52
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013;27:35-53
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Schlude C, Weitz J, Beckhove P. Strong T-cell costimulation can reactivate tumor-antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: results from a phase I clinical study. Int J Oncol 2015;46:71-7
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013;73:7189-98
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
   PubMed Web of Science ®Google Scholar
• Hodi FS, O`Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6:226-32
   Google Scholar
• Schirrmacher V, Bihari AS, Stücker W, Sprenger T. Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report. Oncol Letters 2014;8:2403-6
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Jurianz K, Roth C, et al. Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLT-CML cultures. Int J Oncol 1999;14(2):205-15
   PubMed Web of Science ®Google Scholar
• Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 2015;150:23-32
   PubMed Web of Science ®Google Scholar